Esperion to Report Second Quarter 2025 Financial Results on August 5
Rhea-AI Summary
Esperion (NASDAQ: ESPR) has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before market open. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease patients with elevated LDL-C. Their medications are supported by the 14,000-patient CLEAR Cardiovascular Outcomes Trial. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi) development.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ESPR gained 6.09%, reflecting a notable positive market reaction. Argus tracked a peak move of +14.6% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $16M to the company's valuation, bringing the market cap to $273M at that time.
Data tracked by StockTitan Argus on the day of publication.
ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.
A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When will Esperion (ESPR) report Q2 2025 earnings?
What time is Esperion's Q2 2025 earnings call?
How can I access Esperion's Q2 2025 earnings webcast?
What are Esperion's main products and focus areas?
How many patients were involved in Esperion's CLEAR Cardiovascular Outcomes Trial?
